Researchers with the FDA’s Office of Prescription Drug Promotion (OPDP) plan to continue with a text analysis of proprietary drug name interpretations. After the research was announced last November (86 Fed. Reg. 60254), the agency received 19 comments on the study, which will build on and extend OPDP’s Empirical Study of Promotional Implications of Proprietary Prescription Dr... Read More